Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Nazanin Majd, MD
CONTACT
Lead
M.D. Anderson Cancer Center
With
Primary Objective: 1. Surgical: To evaluate the ability of ulixertinib to penetrate the BBB in patients with recurrent MAPK-activated gliomas (ulixertinib tumor concentration, tumor/plasma ratio) 2. Non-surgical: To assess anti-tumor activity of ulixertinib for patients with recurrent MAPK-activated gliomas (objective response rate (ORR)) Secondary Objectives: 1. To assess anti-tumor activity of ulixertinib for patients with recurrent MAPK-activated gliomas 1. Progression-free-survival (PFS) 2. Overall survival (OS) 3. Disease control rate (DCR) 4. Duration of response (DOR) 5. Time to response (TTR) 6. Time to next intervention 2. To assess safety and tolerability of ulixertinib in MAPK-activated gliomas 3. To evaluate the ability of ulixertinib to reach cerebrospinal fluid (ulixertinib CSF concentration, tumor/CSF ratio)
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted